|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/7072 | |
| A61K 31/551 | |||
| A61P 31/18 |
| (11) | Number of the document | 1420799 |
| (13) | Kind of document | T |
| (96) | European patent application number | 02797744.6 |
| Date of filing the European patent application | 2002-08-21 | |
| (97) | Date of publication of the European application | 2004-05-26 |
| (45) | Date of publication and mention of the grant of the patent | 2006-10-04 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2002/026675 |
| Date | 2002-08-21 |
| (87) | Number | WO 2003/020206 |
| Date | 2003-03-13 |
| (30) | Number | Date | Country code |
| 316745 P | 2001-08-31 | US |
| (72) |
BECHTOLD, Clifford, M., US
|
| (73) |
Bristol-Myers Squibb Company,
P.O. Box 4000, Princeton NJ 08543-4000,
US
|
| (54) | USE OF ATAZANAVIR IN HIV THERAPY |
| USE OF ATAZANAVIR IN HIV THERAPY |